Mersana Therapeutics to Present at Upcoming Investor Conferences
February 02 2023 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that members of
management will present at the following upcoming investor
conferences:
Guggenheim Oncology
Conference |
Format: |
Fireside
Chat |
Date/Time: |
Wednesday, February 8, 2023, at 2:10 p.m. Eastern Time |
SVB Securities Global Biopharma
Conference |
Format: |
Fireside
Chat |
Date/Time |
Wednesday, February 15, 2023, at 1:00 p.m. Eastern Time |
Cowen 43rd
Annual Health Care Conference |
Format: |
Panel
Discussion |
Date/Time: |
Wednesday, March 8, 2023, at 9:10 a.m. Eastern Time |
Oppenheimer 33rd
Annual Healthcare Conference |
Format: |
Presentation |
Date/Time: |
Tuesday, March 14, 2023, at 12:00 p.m. Eastern Time |
Live webcasts of these events will be available on the Investors
& Media section of Mersana’s website at www.mersana.com.
Archived replays will be available for approximately 90 days
following the events.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a
single-arm registrational trial in patients with platinum-resistant
ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi
in combination with carboplatin; and UP-NEXT, a Phase 3 clinical
trial of UpRi as monotherapy maintenance following treatment with
platinum doublets in recurrent platinum-sensitive ovarian cancer.
Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting
B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope
of human epidermal growth factor receptor 2 (HER2), in addition to
other earlier-stage assets. In addition, multiple partners are
using Mersana’s platforms to advance their ADC pipelines. Mersana
routinely posts information that may be useful to investors on the
“Investors & Media” section of its website at
www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024